ClinicalTrials.gg
CompletedNCT02367638Updated Apr 27, 2017

Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults

A Phase 1 interventional study of MG1111 and VARIVAX in Varicella (Chicken Pox), sponsored by Green Cross Corporation. Completed. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-27.

Sponsored by Green Cross Corporation · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether varicella live vaccine is safe and effective in the healthy adults.

02

Conditions studied

  • Varicella (Chicken Pox)

Browse trials for

03

In context

Chickenpox

180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.

This study's planned enrollment of 39 is below the median of 475 across 149 interventional studies indexed under Chickenpox.

Browse Chickenpox studies →

Lead sponsor

Green Cross Corporation is the lead sponsor of 63 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female individuals between 20 and 55 years of age at screening test

    • In the case of female, individuals must be applicable for one of the following;
    • In the case of female of , any negative pregnancy test using urine hCG at screening
    • Menopausal for at least 2 years
    • Surgical sterilization (status after hysterectomy, bilateral oophorectomy, bilateral tubal ligation or the status using other methods)
    • Monogamous relationship with vasectomized partner prior to screening visit
    • Individuals who are used acceptable contraceptive methods from 3 month prior to the subject's study entry to 1 month after vaccination (acceptable contraceptive methods; condom, diaphragm or cervical cap)
  2. If male who is sexually active with the female "of childbearing potential" , the individuals who agree to use any of the acceptable contraceptive methods during this study period and agree to not donate the sperm until 1 month
  3. At screening visits, individuals who are over 55 kg in man, over 50kg in woman and whose ideal body weight is within 20 % ((ideal body weight = (height -100)*0.9)
  4. Individual who has no abnormalities in screening test within 28 days prior to vaccination
  5. Individuals who were voluntarily signed form after receiving education about this study and able to comply with the requirements for the study

Exclusion criteria

Exclusion Criteria:

  1. Individuals who received any other vaccines within 4 weeks prior to the screening visit
  2. Individuals who are planning to receive the other vaccines during this study
  3. Individuals who had wound, scar, tattoo, dermatological disorders or injection affecting safety evaluation
  4. Individuals with alcohol or caffeine abuse or heavy smoker (caffeine : >5 cups/day, alcohol : 210g/week, smoke : 10 /day)
  5. Individuals who received any other product within 90 days prior to vaccination
  6. individuals who donated the whole blood within 60 days or apheresis within 30 days prior to vaccinating investigational product
  7. Individuals who administered with another prescription medicine, herbal medicine within 14 days or over-the-counter drug or vitamins within 7 days before vaccination
  8. Individuals with history or illness affecting immune system (1) individuals with continuously anti-viral therapy within 6 months prior to participating in this study (2) Individuals with leukemia, lymphoma, other malignant neoplasm or hematodyscrasia affecting the bone marrow or lymphatic system (3) Immunodeficient individuals (primary or acquired immunodeficiency states, immunodeficiency, hypogammaglobulinemia, dysgammaglobulinemia) (4) Individuals who are receiving therapy (5) Individuals who have treated immunoglobulin or blood-derived products within 6 months of enrollment (6) Individuals with a family history of congenital or hereditary immunodeficiency
  9. Individuals with any history of other disease or disorder - gastrointestinal, respiratory, renal, hepatic, neurological (Guillain-Barre syndrome), psychiatric or malignant tumor
  10. Individuals with any febrile illness or body temperature ≥38℃ before vaccination
  11. Individuals known or allergy to components of investigational product (including gelatin and neomycin)
  12. Individuals who are any clinically significant abnormality following the investigator's review of the pre-study physical examination, , and clinical laboratory tests
  13. Pregnancy or breastfeeding
  14. Any other ineligible condition at the discretion of the investigator that would be ineligible to participate the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    MG1111

    Biological: MG1111

  • Active comparator
    VARIVAX

    Biological: VARIVAX

Interventions

  • BiologicalMG1111

    Low, Medium, High Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection

  • BiologicalVARIVAX

    VARIVAX is administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. To evaluate the solicited adverse events and unsolicited adverse events during 7 days after vaccination

    Time frame: 7 days

  2. To evaluate the unsolicited adverse events during 42 days after vaccination

    Time frame: 42 days

Secondary outcomes

  1. To evaluate the efficacy of Geometric mean titer (GMT) and GMT ratio using FAMA assay antibody titer at Day 42

    Time frame: 42 days

  2. To evaluate the efficacy of Geometric mean titer (GMT) and GMT ratio using gpELISA antibody titer at Day 42

    Time frame: 42 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015 and a primary completion of Jul 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2015
First posted
Feb 20, 2015
Start
Mar 2015
Primary completionActual
Jul 2015
Last update
Apr 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02367638
Responsible party
Sponsor
First posted
Feb 20, 2015
Start date
Mar 2015
Primary completion
Jul 2015
Last update
Apr 27, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MG1111

Start the discussion